Loading clinical trials...
Loading clinical trials...
Multicenter, non-interventional, retrospective/prospective study of a biological nature, on patients affected by head and neck tumors, for which the collection and use of tissue samples is planned for the study of the mutational profile, the transcriptional profile and the proteomic profile.
The study aims to characterize molecular networks governed by the mutated protein p53 with a relevant role in the development of local recurrence in head and neck tumors HNSCC, in order to identify the main actors involved in resistance to current therapy and try to develop new more effective therapeutic strategies for head and neck tumors. Furthermore, the existence of a significant relationship between the time of onset of recurrence and the deregulation of the identified molecular networks will be studied. This study will therefore allow to: 1. Identify networks associated with the presence of mutation in the TP53 gene relevant in the development of relapse, comparing the tissues of the primary tumor to the respective tissue of the relapse of patients affected by head and neck cancer, by: 1. expression profiles of coding and non-coding RNAs (retrospective cohort) 2. mutational profile by NGS (retrospective cohort) 3. Single cell RNA-sequencing (SC-RNAseq) on samples belonging to the prospective cohort 2. Characterize the molecular mechanisms underlying TP53-dependent networks with a key role in resistance to therapy, using resistance cell systems and in organoid cultures derived from head and neck tumors HNSCC (PDO) (prospective cohort). 3. Identify the best treatment combinations able to target the networks identified as associated with resistance (prospective cohort). 4. To evaluate the response of treatments in vivo using a syngeneic model of head and neck tumors HNSCC (MOC model).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
IRCCS National Cancer institute
Roma, Rome, Italy
Start Date
March 7, 2024
Primary Completion Date
March 7, 2029
Completion Date
March 7, 2029
Last Updated
January 24, 2025
18
ESTIMATED participants
Culture of organoids
BIOLOGICAL
Lead Sponsor
Regina Elena Cancer Institute
NCT06968520
NCT06251050
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions